Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population

Kristina Lagerstedt-Robinson; Anna Rohlin; Christos Aravidis; Beatrice Melin; Margareta Nordling; Marie Stenmark-Askmalm; Annika Lindblom; Mef Nilbert

doi:10.3892/or.2016.5060

Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population

Kristina Lagerstedt-Robinson^*, Anna Rohlin, Christos Aravidis, Beatrice Melin, Margareta Nordling, Marie Stenmark-Askmalm, Annika Lindblom, Mef Nilbert

^*Corresponding author af dette arbejde

19 Citationer (Scopus)

Abstract

Lynch syndrome caused by constitutional mismatch-repair defects is one of the most common hereditary cancer syndromes with a high risk for colorectal, endometrial, ovarian and urothelial cancer. Lynch syndrome is caused by mutations in the mismatch repair (MMR) genes i.e., MLH1, MSH2, MSH6 and PMS2. After 20 years of genetic counseling and genetic testing for Lynch syndrome, we have compiled the mutation spectrum in Sweden with the aim to provide a population-based perspective on the contribution from the different MMR genes, the various types of mutations and the influence from founder mutations. Mutation data were collected on a national basis from all laboratories involved in genetic testing. Mutation analyses were performed using mainly Sanger sequencing and multiplex ligation-dependent probe amplification. A total of 201 unique disease-predisposing MMR gene mutations were identified in 369 Lynch syndrome families. These mutations affected MLH1 in 40%, MSH2 in 36%, MSH6 in 18% and PMS2 in 6% of the families. A large variety of mutations were identified with splice site mutations being the most common mutation type in MLH1 and frameshift mutations predominating in MSH2 and MSH6. Large deletions of one or several exons accounted for 21% of the mutations in MLH1 and MSH2 and 22% in PMS2, but were rare (4%) in MSH6. In 66% of the Lynch syndrome families the variants identified were private and the effect from founder mutations was limited and predominantly related to a Finnish founder mutation that accounted for 15% of the families with mutations in MLH1. In conclusion, the Swedish Lynch syndrome mutation spectrum is diverse with private MMR gene mutations in two-thirds of the families, has a significant contribution from internationally recognized mutations and a limited effect from founder mutations.

Originalsprog	Engelsk
Tidsskrift	Oncology Reports
Vol/bind	36
Udgave nummer	5
Sider (fra-til)	2823-2835
Antal sider	13
ISSN	1021-335X
DOI	https://doi.org/10.3892/or.2016.5060
Status	Udgivet - 1 nov. 2016
Udgivet eksternt	Ja

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.3892/or.2016.5060

downloadForlagets udgivne version, 387 KB

Citationsformater

@article{6000527fd1e34d78a4847baa72a0aa48,

title = "Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population",

abstract = "Lynch syndrome caused by constitutional mismatch-repair defects is one of the most common hereditary cancer syndromes with a high risk for colorectal, endometrial, ovarian and urothelial cancer. Lynch syndrome is caused by mutations in the mismatch repair (MMR) genes i.e., MLH1, MSH2, MSH6 and PMS2. After 20 years of genetic counseling and genetic testing for Lynch syndrome, we have compiled the mutation spectrum in Sweden with the aim to provide a population-based perspective on the contribution from the different MMR genes, the various types of mutations and the influence from founder mutations. Mutation data were collected on a national basis from all laboratories involved in genetic testing. Mutation analyses were performed using mainly Sanger sequencing and multiplex ligation-dependent probe amplification. A total of 201 unique disease-predisposing MMR gene mutations were identified in 369 Lynch syndrome families. These mutations affected MLH1 in 40%, MSH2 in 36%, MSH6 in 18% and PMS2 in 6% of the families. A large variety of mutations were identified with splice site mutations being the most common mutation type in MLH1 and frameshift mutations predominating in MSH2 and MSH6. Large deletions of one or several exons accounted for 21% of the mutations in MLH1 and MSH2 and 22% in PMS2, but were rare (4%) in MSH6. In 66% of the Lynch syndrome families the variants identified were private and the effect from founder mutations was limited and predominantly related to a Finnish founder mutation that accounted for 15% of the families with mutations in MLH1. In conclusion, the Swedish Lynch syndrome mutation spectrum is diverse with private MMR gene mutations in two-thirds of the families, has a significant contribution from internationally recognized mutations and a limited effect from founder mutations.",

keywords = "EPCAM, Hereditary colorectal cancer, HNPCC, Lynch syndrome, MLH1, MSH2, MSH6",

author = "Kristina Lagerstedt-Robinson and Anna Rohlin and Christos Aravidis and Beatrice Melin and Margareta Nordling and Marie Stenmark-Askmalm and Annika Lindblom and Mef Nilbert",

year = "2016",

month = nov,

day = "1",

doi = "10.3892/or.2016.5060",

language = "English",

volume = "36",

pages = "2823--2835",

journal = "Oncology Reports",

issn = "1021-335X",

publisher = "Spandidos Publications",

number = "5",

}

TY - JOUR

T1 - Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population

AU - Lagerstedt-Robinson, Kristina

AU - Rohlin, Anna

AU - Aravidis, Christos

AU - Melin, Beatrice

AU - Nordling, Margareta

AU - Stenmark-Askmalm, Marie

AU - Lindblom, Annika

AU - Nilbert, Mef

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Lynch syndrome caused by constitutional mismatch-repair defects is one of the most common hereditary cancer syndromes with a high risk for colorectal, endometrial, ovarian and urothelial cancer. Lynch syndrome is caused by mutations in the mismatch repair (MMR) genes i.e., MLH1, MSH2, MSH6 and PMS2. After 20 years of genetic counseling and genetic testing for Lynch syndrome, we have compiled the mutation spectrum in Sweden with the aim to provide a population-based perspective on the contribution from the different MMR genes, the various types of mutations and the influence from founder mutations. Mutation data were collected on a national basis from all laboratories involved in genetic testing. Mutation analyses were performed using mainly Sanger sequencing and multiplex ligation-dependent probe amplification. A total of 201 unique disease-predisposing MMR gene mutations were identified in 369 Lynch syndrome families. These mutations affected MLH1 in 40%, MSH2 in 36%, MSH6 in 18% and PMS2 in 6% of the families. A large variety of mutations were identified with splice site mutations being the most common mutation type in MLH1 and frameshift mutations predominating in MSH2 and MSH6. Large deletions of one or several exons accounted for 21% of the mutations in MLH1 and MSH2 and 22% in PMS2, but were rare (4%) in MSH6. In 66% of the Lynch syndrome families the variants identified were private and the effect from founder mutations was limited and predominantly related to a Finnish founder mutation that accounted for 15% of the families with mutations in MLH1. In conclusion, the Swedish Lynch syndrome mutation spectrum is diverse with private MMR gene mutations in two-thirds of the families, has a significant contribution from internationally recognized mutations and a limited effect from founder mutations.

AB - Lynch syndrome caused by constitutional mismatch-repair defects is one of the most common hereditary cancer syndromes with a high risk for colorectal, endometrial, ovarian and urothelial cancer. Lynch syndrome is caused by mutations in the mismatch repair (MMR) genes i.e., MLH1, MSH2, MSH6 and PMS2. After 20 years of genetic counseling and genetic testing for Lynch syndrome, we have compiled the mutation spectrum in Sweden with the aim to provide a population-based perspective on the contribution from the different MMR genes, the various types of mutations and the influence from founder mutations. Mutation data were collected on a national basis from all laboratories involved in genetic testing. Mutation analyses were performed using mainly Sanger sequencing and multiplex ligation-dependent probe amplification. A total of 201 unique disease-predisposing MMR gene mutations were identified in 369 Lynch syndrome families. These mutations affected MLH1 in 40%, MSH2 in 36%, MSH6 in 18% and PMS2 in 6% of the families. A large variety of mutations were identified with splice site mutations being the most common mutation type in MLH1 and frameshift mutations predominating in MSH2 and MSH6. Large deletions of one or several exons accounted for 21% of the mutations in MLH1 and MSH2 and 22% in PMS2, but were rare (4%) in MSH6. In 66% of the Lynch syndrome families the variants identified were private and the effect from founder mutations was limited and predominantly related to a Finnish founder mutation that accounted for 15% of the families with mutations in MLH1. In conclusion, the Swedish Lynch syndrome mutation spectrum is diverse with private MMR gene mutations in two-thirds of the families, has a significant contribution from internationally recognized mutations and a limited effect from founder mutations.

KW - EPCAM

KW - Hereditary colorectal cancer

KW - HNPCC

KW - Lynch syndrome

KW - MLH1

KW - MSH2

KW - MSH6

U2 - 10.3892/or.2016.5060

DO - 10.3892/or.2016.5060

M3 - Journal article

C2 - 27601186

AN - SCOPUS:84989967242

SN - 1021-335X

VL - 36

SP - 2823

EP - 2835

JO - Oncology Reports

JF - Oncology Reports

IS - 5

ER -

Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater